ArticleAdvanced functional materials2025
Multifunctional Superparamagnetic Copper Iron Oxide Nanoparticles for Synergistic Cancer Therapy via Magnetic Hyperthermia, Oxidative Stress and Immune Reprogramming.
Article in Advanced functional materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Tumor acid-triggered sericin prodrug colloidal system for enhanced photodynamic and ferroptosis therapy of breast cancer.Materials today. Bio · 2026Article
- Global trends and hotspots in oxidative stress and esophageal cancer research: a comprehensive bibliometric and visualized analysis based on the Web of Science Core Collection (1998-2026).Journal of thoracic disease · 2026Article
- Peptide Aptamer-Enabled Nanoplasmonic Digital Immunoassay for Ultrasensitive Cytokine Sensing in Early Inflammation and Immune Modulation.ACS sensors · 2026Article
- Magnetically Controlled Nanocarriers for Site-Specific Drug Delivery and Theranostics in Cancer Precision Medicine.Molecular imaging and biology · 2026Review
- A biomimetic magnetic MOF-based nanoplatform for HMaterials today. Bio · 2026Article
- Recent advances in enhancing the luminescence efficiency of rare earth upconversion nanoparticles for biomedical applications.RSC advances · 2026Review
- Bidirectional regulation between ferroptosis and tumor-associated macrophages: mechanisms, strategies, and therapeutic perspectives.Frontiers in oncology · 2026Review
- Wearable sensors: in situ detection tools for plant physiological markers and growth environment information.Mikrochimica acta · 2025Review
- Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery.Bioactive materials · 2025Review
- Mechanism and application of copper-based nanomedicines in activating tumor immunity through oxidative stress modulation.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Aggressive cancers, characterized by high metastatic potential and resistance to conventional therapies, present a significant challenge in oncology. Current treatments often fail to effectively target metastasis, recurrence, and the immunosuppressive tumor microenvironment, while causing significant off-target toxicity. Here, we present superparamagnetic copper iron oxide nanoparticles (SCIONs) as a multifunctional platform that integrates magnetic hyperthermia therapy, immune modulation, and targeted chemotherapeutic delivery, aiming to provide a more comprehensive cancer treatment. Specifically, SCIONs generate localized hyperthermia under an alternating magnetic field while delivering a copper-based anticancer agent, resulting in a synergistic anticancer effect. The hyperthermia induced by SCIONs caused ER stress and ROS production, leading to significant tumor cell death, while the copper complex further enhanced oxidative stress, ferroptosis, and apoptosis. Beyond direct cytotoxicity, SCIONs disrupted the tumor microenvironment by inhibiting cancer-associated fibroblasts, downregulating epithelial-mesenchymal transition markers, and reducing cell migration and invasion, thereby limiting metastasis. Additionally, SCION-based therapy reprogrammed the immune microenvironment by inducing immunogenic cell death and enhancing dendritic cell activation, resulting in increased CD8+ T cell infiltration and amplified antitumor immunity. This integrated approach targets primary and metastatic tumors while mitigating immunosuppression, offering a promising next-generation therapy for combating cancer with enhanced efficacy and reduced side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.